Medigene AG to Announce H1 2024 Financial Results on August 14, 2024
Planegg/Martinsried, August 8, 2024. Medigene AG, an oncology platform company that focuses on T cell receptor (TCR)-guided therapies for cancer treatment, announced that it will disclose its financial results for the first half of 2024 and provide a corporate update on Wednesday, August 14, 2024. The announcement will be followed by a conference call at 3:30 PM CEST / 9:30 AM EDT on the same day.
This update will include not only the financial performance for the first six months of 2024 but also information on a new collaboration with WuXi Biologics, as previously disclosed in a press release dated August 8, 2024.
The specifics for the upcoming conference call and webcast are as follows:
- Date: Wednesday, August 14, 2024
- Time: 3:30 PM CEST (9:30 AM EDT)
- Conference Call: Interested parties can register using the provided link to receive dial-in details.
- Webcast: A live webcast will be available, and participants can join through the specified link.
Participants are encouraged to dial in 10 minutes before the start to ensure the conference call begins on time. An archived version of the webcast will be available on the Investors & Media section of Medigene’s website after the call.
About Medigene AG:
Medigene AG is a company specialized in immuno-oncology, with a focus on developing T cell receptor (TCR)-guided treatments aimed at eradicating cancer. The company's End-to-End Platform is designed to produce optimal T cell receptors that are sensitive, specific, and safe. These TCRs are utilized in various therapeutic applications, including T cell receptor engineered T cell (TCR-T) therapies, TCR-guided T cell engager therapies, and TCR-natural killer cell therapies. These therapies are part of both Medigene’s internal product pipeline and collaborations with partners.
Medigene’s leading TCR-T program, MDG1015, is a promising therapy designed to treat multiple solid tumor types. The technology from the End-to-End Platform enhances and arms T cells to counteract the immunosuppressive tumor microenvironment. This ensures that the T cell drug products are safe, effective, and durable. MDG1015 is scheduled for an Investigational New Drug (IND) filing in the third quarter of 2024 and a Clinical Trial Application (CTA) filing in the fourth quarter of 2024. More details can be found on the company's website at www.medigene.com.
Medigene AG is poised to make significant advancements in the field of immuno-oncology, aiming to bring innovative cancer treatments to market.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
